Hakon Ramberg
Overview
Explore the profile of Hakon Ramberg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
322
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Guldvik I, Ramberg H, Kristensen G, Roder A, Mills I, Lilleby W, et al.
World J Urol
. 2024 Feb;
42(1):95.
PMID: 38386171
Purpose: The primary objective was to establish whether blood-based leucine-rich alpha-2-glycoprotein (LRG1) can predict outcomes in patients with locally advanced prostate cancer undergoing androgen-deprivation therapy (ADT) and radiotherapy (RT) and...
2.
Nunes-Xavier C, Emaldi M, Guldvik I, Ramberg H, Tasken K, Maelandsmo G, et al.
Pathol Res Pract
. 2022 Dec;
241:154243.
PMID: 36481650
Prostate cancer diagnosis and early stratification is an important aspect to avoid undertreatment of high-risk prostate cancer patients. Major Vault Protein (MVP) has been proposed as a prognostic biomarker in...
3.
Guldvik I, Braadland P, Sivanesan S, Ramberg H, Kristensen G, Tennstedt P, et al.
Eur Urol Open Sci
. 2022 Nov;
45:68-75.
PMID: 36353660
Background: After radical prostatectomy (RP), depending on stage, up to 40% of patients with prostate cancer (PCa) will experience biochemical failure (BF). Despite salvage therapy, approximately one-third of these patients...
4.
Guldvik I, Zuber V, Braadland P, Grytli H, Ramberg H, Lilleby W, et al.
Eur Urol Open Sci
. 2021 Aug;
21:51-60.
PMID: 34337468
Background: More accurate risk assessments are needed to improve prostate cancer management. Objective: To identify blood-based protein biomarkers that provided prognostic information for risk stratification. Design Setting And Participants: Mass...
5.
Guerriero I, Ramberg H, Sagini K, Ramirez-Garrastacho M, Tasken K, Llorente A
PLoS One
. 2021 Jun;
16(6):e0253828.
PMID: 34191854
The β2-adrenergic receptor has been shown to be involved in neuroendocrine differentiation and to contribute to the development of aggressive prostate cancer. In this study we have investigated whether miR-196a...
6.
Ramberg H, Richardsen E, de Souza G, Rakaee M, Stensland M, Braadland P, et al.
Carcinogenesis
. 2021 Feb;
42(5):685-693.
PMID: 33609362
The demographic shift toward an older population will increase the number of prostate cancer cases. A challenge in the treatment of prostate cancer is to avoid undertreatment of patients at...
7.
Braadland P, Ramberg H, Grytli H, Urbanucci A, Nielsen H, Guldvik I, et al.
Mol Cancer Res
. 2019 Aug;
17(11):2154-2168.
PMID: 31395667
The incidence of treatment-related neuroendocrine prostate cancer (t-NEPC) is rising as more potent drugs targeting the androgen signaling axis are clinically implemented. Neuroendocrine transdifferentiation (NEtD), an putative initial step in...
8.
Moen L, Ramberg H, Zhao S, Grytli H, Sveen A, Berge V, et al.
Urol Oncol
. 2016 Nov;
35(3):111.e1-111.e8.
PMID: 27838142
Background: Today overtreatment of indolent prostate cancers and undertreatment of aggressive prostate cancer are a major concern for patients, their families, and the health care system. New biomarkers distinguishing indolent...
9.
Ramberg H, Grytli H, Nygard S, Wang W, Ogren O, Zhao S, et al.
Int J Cancer
. 2016 Jun;
139(8):1810-20.
PMID: 27273830
There is a great need to identify new and better prognostic and predictive biomarkers to stratify prostate cancer patients for optimal treatment. The aims of this study were to characterize...
10.
Braadland P, Grytli H, Ramberg H, Katz B, Kellman R, Gauthier-Landry L, et al.
Oncotarget
. 2015 Dec;
7(2):1878-94.
PMID: 26646591
The underlying mechanisms responsible for the development of castration-resistant prostate cancer (CRPC) in patients who have undergone androgen deprivation therapy are not fully understood. This is the first study to...